- Home
- GORO vs MRKR Comparison
GORO vs MRKR Comparison
Compare GORO & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- MRKR
- Stock Information
- Founded
- GORO 1998
- MRKR N/A
- Country
- GORO United States
- MRKR United States
- Employees
- GORO N/A
- MRKR N/A
- Industry
- GORO Precious Metals
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- GORO Basic Materials
- MRKR Health Care
- Exchange
- GORO Nasdaq
- MRKR Nasdaq
- Market Cap
- GORO 40.2M
- MRKR 35.8M
- IPO Year
- GORO N/A
- MRKR N/A
- Fundamental
- Price
- GORO $0.16
- MRKR $3.10
- Analyst Decision
- GORO Strong Buy
- MRKR Strong Buy
- Analyst Count
- GORO 1
- MRKR 1
- Target Price
- GORO $1.75
- MRKR $19.00
- AVG Volume (30 Days)
- GORO 2.5M
- MRKR 25.8K
- Earning Date
- GORO 11-05-2024
- MRKR 11-14-2024
- Dividend Yield
- GORO N/A
- MRKR N/A
- EPS Growth
- GORO N/A
- MRKR N/A
- EPS
- GORO N/A
- MRKR N/A
- Revenue
- GORO $73,897,000.00
- MRKR $5,395,849.00
- Revenue This Year
- GORO N/A
- MRKR $35.94
- Revenue Next Year
- GORO $48.90
- MRKR N/A
- P/E Ratio
- GORO N/A
- MRKR N/A
- Revenue Growth
- GORO N/A
- MRKR 79.04
- 52 Week Low
- GORO $0.12
- MRKR $2.44
- 52 Week High
- GORO $0.71
- MRKR $6.16
- Technical
- Relative Strength Index (RSI)
- GORO 40.99
- MRKR 42.91
- Support Level
- GORO $0.12
- MRKR $2.91
- Resistance Level
- GORO $0.17
- MRKR $3.25
- Average True Range (ATR)
- GORO 0.01
- MRKR 0.38
- MACD
- GORO 0.01
- MRKR -0.11
- Stochastic Oscillator
- GORO 73.25
- MRKR 17.72
About GORO Gold Resource Corporation
Gold Resource Corp is a gold and silver producer, developer, and explorer with operations in Oaxaca, Mexico, and Nevada, USA. It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.